New study shows high concentration of lutein and zeaxanthin in the macula is associated with reduced glare disability, improved photostress recovery, and contrast enhancement
During the baseline testing of 111 healthy young subjects in a one-year, randomized, placebo-controlled, double-blind study, lead author M Dengler and associates measured macular pigment, glare disability, photostress recovery time and contrast enhancement at the Vision Science Laboratory of the University of Georgia. Macular pigment varied widely among the subjects but was significantly and positively correlated with glare disability, photostress recovery time and contrast enhancement. The current study is part of an intervention study, now in progress, which is testing whether supplementing with FloraGLO® Lutein and OPTISHARP® Zeaxanthin leads to improved visual performance by increasing the level of macular pigment.
Glare from bright lights like the sun and high intensity automobile headlights are known to reduce visibility: when too intense glare can cause a temporary loss of vision. Glare is encountered during such normal activities as driving, skiing, boating and golfing. In addition, objects surrounded by blue light have reduced contrast.
For this intervention study, DSM Nutritional Products and Kemin Health, L.C., supplied the FloraGLO® Lutein (10mg lutein/day) and OPTISHARP® Zeaxanthin (2 mg zeaxanthin/day) tablets and matching placebo tablets. The test tablets used Actilease® technology in order to maximise the absorption of lutein and zeaxanthin.
OPTISHARP and Actilease are registered trademarks of DSM.
FloraGLO is a registered trademark of Kemin Industries, Inc.